title: Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.
abstract: Serum cystatin C concentration is an alternative measure of kidney function that is less affected by age, sex or muscle mass, and is a more sensitive indicator of early renal dysfunction than creatinine-based estimations of glomerular filtration rate. Cardiovascular sequela increases progressively with the increase in left ventricular mass. Our goal was to evaluate the effect of olmesartan medoxomil on cystatin C levels and left ventricular hypertrophy (LVH) in patients with hypertension. Forty-four newly diagnosed hypertensive patients (27 women and 17 men) were recruited in the study. Olmesartan medoxomil (20mg/day) was started and the patients were followed up for 6 months. Baseline echocardiographic findings (i.e. left ventricular mass index), serum creatinine, urine albumin/creatinine ratio (ACR) and serum cystatin C levels were compared with the levels of these variables measured at the end of 6-month follow-up period. After 6 months of treatment with olmesartan medoxomil, there was a significant reduction in systolic and diastolic blood pressure (p<0.001) and in urine ACR (p=0.04). Mean serum cystatin C levels decreased from 1.61+/-0.24 mg/l to 1.31+/-0.29 mg/l (p<0.001). Olmesartan medoxomil treatment also reduced left ventricular mass index (p<0.001) and LVH (p<0.001). Our findings indicate that olmesartan medoxomil decreases serum cystatin C levels, urine ACR and reduces LVH in patients with hypertension. To our knowledge, this study is the first to show that olmesartan medoxomil decreases serum cystatin C levels, indicating that in patients with essential hypertension it may counteract end organ damage.
authors.affiliation: Medicine Faculty Department of Cardiology, Duzce University, Duzce, Turkey.
authors.forename: Sinan
authors.initials: S
authors.lastname: Albayrak
authors.forename: Serkan
authors.initials: S
authors.lastname: Ordu
authors.forename: Hakan
authors.initials: H
authors.lastname: Ozhan
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yazici
authors.forename: Mesut
authors.initials: M
authors.lastname: Aydin
authors.forename: Recai
authors.initials: R
authors.lastname: Alemdar
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kaya
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D055316:Cystatin C / Q000097:blood*; D003971:Diastole / Q000187:drug effects; D004452:Echocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000097:blood / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D000068557:Olmesartan Medoxomil; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D055316:Cystatin C; D007093:Imidazoles; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil